Metapro 3D 25 Tablet ER is a combination antihypertensive medication containing Chlorthalidone (12.5 mg), Metoprolol Succinate (23.75 mg), and Telmisartan (40 mg). This extended-release formulation is indicated for the management of hypertension, particularly in patients requiring multiple mechanisms of blood pressure control. Chlorthalidone, a thiazide-like diuretic, promotes sodium and water excretion, reducing plasma volume and peripheral resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive effects of angiotensin II, leading to vasodilation and reduced aldosterone secretion. The combined action of these agents provides synergistic antihypertensive effects, improving blood pressure control and reducing cardiovascular risk. Metapro 3D 25 Tablet ER is typically administered once daily, with dosage adjustments based on clinical response and tolerability. It is contraindicated in patients with hypersensitivity to any component, severe renal or hepatic impairment, or pregnancy. Monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. This combination therapy offers a convenient and effective option for patients with hypertension requiring multi-drug regimens.